eNavvi

Cover Block

Attribute	Details
Name	eNavvi
Tagline	Free digital prescribing platform for clinicians, offering real-time cash price visibility and electronic prescription routing.
Headquarters	Los Angeles, California
Founded	2017
Stage	Seed
Business Model	B2B2C
Industry	Healthtech
Technology	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$840,000)

Links

• Website: https://enavvi.com/home
• LinkedIn: https://www.linkedin.com/company/enavvi
• Google Play: https://play.google.com/store/apps/details?id=com.enavvi.app&hl=en_US
• App Store: https://apps.apple.com/us/app/enavvi/id6478748107

Executive Summary

eNavvi is a free digital prescribing platform that embeds real-time medication cost transparency directly into a clinician's workflow, a bet that reducing patient out-of-pocket expenses at the point of care is a durable wedge into the $500 billion U.S. prescription drug market [eNavvi]. The company, founded in 2017 by a practicing physician and an operations specialist, has operated as a bootstrapped venture, raising over $840,000 from a broad base of individual investors before launching a formal $1 million seed round [eNavvi]. Its core product surfaces patient-specific insurance coverage and cash prices for medications, with a particular focus on generics and compounded drugs, and routes prescriptions to a curated network of pharmacies, including a partnership with Mark Cuban Cost Plus Drug Company [PR Newswire].

The founding team is led by Ahmed Yusuf, MD, whose clinical practice informs the product's design, and Muhammad Khan, who handles healthcare operations and technology [eNavvi]. The business model is predicated on being free for clinicians, with the company's website stating it generates revenue from pharmacy partners and potential future enterprise services [eNavvi]. For investors, the next 12-18 months will be defined by the company's ability to convert its nationwide availability into documented health system deployments and to demonstrate that its partner-driven revenue can scale meaningfully beyond its current crowdfunding stage.

Data Accuracy: YELLOW -- Core product and team details are confirmed via company sources; funding figures are self-reported without independent verification.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$840,000)

How the Company Got Here

Founded in 2017, eNavvi is a Los Angeles-based health-tech venture that began as a bootstrapped, founder-led project. The company’s origin is rooted in the clinical experience of its co-founder, Ahmed Yusuf, a practicing physician, who sought to address the opaque and often prohibitive cost of medications at the point of prescribing [eNavvi]. The initial development and early market validation were self-funded, with the company describing a cumulative raise of over $840,000 from more than 70 investors prior to its current funding round [eNavvi].

Key operational milestones have centered on product launches and partnership development. The platform became available nationwide across all 50 U.S. states, offering web and mobile applications for clinicians [eNavvi]. A significant strategic partnership was announced with the Mark Cuban Cost Plus Drug Company, integrating its low-cost medication pricing into eNavvi’s prescribing workflow [PR Newswire]. More recently, the company expanded its focus on specialty medications by launching a nationwide compound pharmacy network and inviting accredited pharmacy partners to join its marketplace [PR Newswire].

Data Accuracy: YELLOW -- Key founding and operational milestones are confirmed by the company's own materials and press releases, but the early funding history lacks independent corroboration.

Product and Technology

The product is a free, point-of-care software layer that inserts price transparency directly into the prescribing workflow. eNavvi's platform, available via web and mobile apps, allows clinicians to search for medications and see real-time, patient-specific insurance coverage and cash prices before sending a prescription [eNavvi].

The platform emphasizes access to cash-price generics and compounded drugs. It integrates a prescription marketplace that routes orders to a curated network of over 7,000 independent and national grocery pharmacy chains [eNavvi]. A key public partnership with the Mark Cuban Cost Plus Drug Company embeds that entity's low cash prices as a selectable option for prescribers [PR Newswire]. Functionally, eNavvi 3.0 is described as fully enabled for electronic prescribing (ePrescribe), while its capability for Electronic Prescribing of Controlled Substances (EPCS) remains in an invite-only beta phase [eNavvi].

Data Accuracy: YELLOW -- Product claims are consistent across the company's website and press releases, but technical implementation details and backend architecture are not publicly verified.

Where the Demand Sits

A market defined by opaque pricing and patient cost burden is increasingly a target for regulatory and commercial intervention. eNavvi operates at the intersection of two converging trends: the push for prescription drug price transparency and the shift toward cash-pay and compounded medications as patients navigate high-deductible plans and coverage gaps.

The broader U.S. e-prescribing market was valued at approximately $1.2 billion in 2021 and is projected to grow to over $4.5 billion by 2030 [Grand View Research, 2022]. U.S. out-of-pocket spending on retail prescription drugs was estimated at $63 billion in 2022 [KFF, 2023].

Metric	Value
U.S. E-Prescribing Market 2021	$1.2B
Projected Market 2030	$4.5B
U.S. Out-of-Pocket Rx Spend 2022	$63B

Data Accuracy: YELLOW -- Market sizing figures are from analogous, third-party industry reports. Direct TAM/SAM for eNavvi's specific transparency niche is not publicly available.

Competitive Landscape

eNavvi competes not by displacing the electronic health record but by inserting a free, cost-transparent prescribing layer into the existing clinician workflow. The landscape splits into three segments: incumbent e-prescribing and EHR giants (Epic, Cerner), PBM and drug pricing tools, and prescription discount platforms (GoodRx, Mark Cuban Cost Plus Drug Company). eNavvi's partnership with MCCPDC coopts a potential competitor by making it a destination within its own provider-facing workflow [MobiHealthNews].

Data Accuracy: YELLOW -- Competitive analysis is inferred from company positioning and known market segments; no direct competitor data is publicly cited.

Opportunity

The potential prize for eNavvi is a fundamental reordering of prescription economics, capturing value from the billions spent annually on medication non-adherence and opaque pharmacy pricing. The company's core wedge, a free, clinician-facing tool, sidesteps the sales friction of traditional enterprise software.

Scenario	What happens	Catalyst
Pharmacy Network Monetization	eNavvi transitions from a free clinician tool to a paid marketplace for pharmacies.	Formal launch of a pharmacy partnership program.
Health System Integration	Large outpatient clinics adopt eNavvi as a cost-containment module.	A pilot deployment with a named health system.
Regulatory Tailwind	State or federal legislation mandating real-time benefit tools expands the market.	Passage of a bill like the Modernizing and Ensuring PBM Accountability Act.

Data Accuracy: YELLOW -- Growth scenarios and market logic are inferred from cited partnerships and product claims; specific financial projections and detailed comparable valuations are not publicly available.

Sources

1. [eNavvi] eNavvi | Free Digital Prescribing Platform for Clinicians | https://enavvi.com/home
2. [eNavvi] eNavvi | Crowdfunding | https://enavvi.com/Crowdfunding
3. [PR Newswire] eNavvi Expands Nationwide Compound Pharmacy Network, Invites Accredited Pharmacy Partners | https://www.prnewswire.com/news-releases/enavvi-expands-nationwide-compound-pharmacy-network-invites-accredited-pharmacy-partners-302509210.html
4. [LinkedIn] eNavvi | LinkedIn | https://www.linkedin.com/company/enavvi
5. [Grand View Research, 2022] Grand View Research Report on E-Prescribing Market | https://www.grandviewresearch.com/industry-analysis/e-prescribing-market
6. [KFF, 2023] Kaiser Family Foundation Analysis of U.S. Prescription Drug Spending | https://www.kff.org/health-costs/issue-brief/what-drives-health-spending-in-the-u-s/
7. [MobiHealthNews] eNavvi partners with Mark Cuban Cost Plus Drug Company | https://www.mobihealthnews.com/news/enavvi-partners-mark-cuban-cost-plus-drug-company
8. [eNavvi] eNavvi | Partnerships | https://enavvi.com/partnerships